Regeneron Pharmaceuticals
REGN
$614.98
+0.46%
Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes treatments for serious medical conditions, including eye diseases, cardiovascular disease, cancer, and inflammation. The company has established itself as a major player with a diversified portfolio anchored by blockbuster drugs like Eylea for ophthalmology and Dupixent in immunology, developed through key partnerships with Sanofi and Bayer. The current investor narrative is dominated by a significant clinical setback, specifically the Phase 3 failure of a key oncology drug combination in May 2026, which has pressured the stock and raised questions about its growth pipeline beyond its established franchises, even as the company navigates regulatory dynamics like recent drug pricing agreements.…
REGN
Regeneron Pharmaceuticals
$614.98
Related headlines
REGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $799.47 and implied upside of +30.0% versus the current price.
Average Target
$799.47
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$492 - $799
Analyst target range
Analyst coverage appears limited in the provided dataset, with only 11 analysts cited in the estimates data, and no explicit consensus recommendation, average target price, or target range is available from the primary analyst data input. The lack of a clear consensus target and the minimal number of analysts suggest that while Regeneron is a large-cap company, detailed public targets may be sparse or the data provided is incomplete; this does not typically imply a lack of institutional interest but rather that the available dataset is insufficient for a detailed sentiment analysis. Without a target range, it is impossible to gauge the bull and bear cases quantitatively; however, the recent institutional ratings show a mix of 'Buy' and 'Hold' equivalents from major firms with no downgrades immediately following the Q4 earnings in February, though the clinical failure in May likely prompted reassessments not captured in this data.
REGN Technical Analysis
The prevailing price trend is a sharp downtrend from recent highs, with the stock down 17.42% over the last six months and 21.15% year-to-date as of June 12, 2026. The current price of $612.14 sits at approximately 52% of its 52-week range ($503.25 to $821.11), indicating the stock is trading near the midpoint but has experienced a substantial correction from its highs, suggesting a shift from momentum to a potential value or consolidation phase. Recent momentum is decisively negative and accelerating, with the stock down 14.97% over the past month and 17.92% over the past three months, a stark divergence from its positive 17.30% one-year return and signaling a significant near-term bearish reversal likely driven by negative clinical trial news. Key technical support is the 52-week low of $503.25, while resistance is the 52-week high of $821.11; a breakdown below the $600 level could test the $503 support, whereas a recovery above the recent breakdown point near $700 would be needed to signal stabilization. The stock's beta of 0.238 indicates it has been significantly less volatile than the broader market (SPY), which is unusual for a biotech but may reflect its large-cap, commercial-stage profile; however, the recent -14.97% monthly drop versus SPY's -0.08% shows severe idiosyncratic risk.
Beta
0.24
0.24x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$503-$821
Price range past year
Annual Return
+16.2%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -11.9% | +2.1% |
| 3m | -19.0% | +12.5% |
| 6m | -18.0% | +12.4% |
| 1y | +16.2% | +26.4% |
| ytd | -20.8% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $3.88 billion representing a 2.51% year-over-year increase; however, examining sequential quarters reveals volatility, with revenue dipping from $3.75 billion in Q3 to $3.02 billion in Q1 2025 before recovering, indicating some lumpiness in sales, primarily driven by the core Product segment ($1.67B) and Collaboration Revenue ($1.97B). The company remains highly profitable with strong margins, posting Q4 2025 net income of $844.6 million and a gross margin of 84.95%, though net margin compressed to 21.74% in Q4 from 38.89% in Q3, reflecting significant quarterly variability in profitability, largely influenced by collaboration accounting and R&D spending. The balance sheet is exceptionally strong with low financial risk, evidenced by a debt-to-equity ratio of just 0.087, a robust current ratio of 4.13, and substantial trailing twelve-month free cash flow of $4.08 billion, providing ample internal resources to fund its $1.63 billion quarterly R&D expenditure and share repurchases without reliance on external financing.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given Regeneron's consistent profitability with positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 17.92x, while the forward PE is significantly lower at 11.38x, indicating the market expects a substantial earnings rebound in the coming year, likely pricing in recovery from the recent clinical setback and continued growth from core products. Compared to typical biotechnology industry averages, a trailing PE in the high-teens is generally reasonable, though a forward PE of 11.4x suggests a discount, which may reflect heightened pipeline risk and margin pressure concerns post the Phase 3 failure, offsetting the company's strong cash generation. Historically, the stock's own trailing PE has ranged widely; the current 17.92x is below the 23.51x seen at the end of Q4 2025 and well below peaks above 30x in early 2024, placing it in the lower half of its recent historical range, which could indicate a valuation reset to more conservative levels following the negative catalyst.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
